Cypress Capital Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.33M Buy
138,473
+8,227
+6% +$215K 0.31% 76
2026
Q1
$3.66M Buy
130,246
+6,603
+5% +$176K 0.41% 61
2025
Q4
$3.08M Buy
123,643
+9,423
+8% +$238K 0.34% 68
2025
Q3
$2.91M Buy
114,220
+102,210
+851% +$2.52M 0.35% 72
2025
Q2
$291K Sell
12,010
-101,055
-89% -$2.36M 0.04% 195
2025
Q1
$2.87M Buy
113,065
+8,968
+9% +$235K 0.38% 64
2024
Q4
$2.76M Sell
104,097
-17,217
-14% -$467K 0.34% 66
2024
Q3
$3.51M Buy
121,314
+3,196
+3% +$93.2K 0.39% 64
2024
Q2
$3.3M Sell
118,118
-15,538
-12% -$428K 0.4% 61
2024
Q1
$3.71M Buy
133,656
+12,518
+10% +$347K 0.44% 61
2023
Q4
$3.49M Buy
121,138
+8,100
+7% +$245K 0.45% 58
2023
Q3
$3.75M Buy
113,038
+2,312
+2% +$81.8K 0.54% 50
2023
Q2
$4.06M Sell
110,726
-34,488
-24% -$1.34M 0.59% 46
2023
Q1
$5.92M Buy
145,214
+1,363
+0.9% +$58.9K 0.91% 30
2022
Q4
$7.37M Buy
143,851
+5,116
+4% +$245K 1.11% 20
2022
Q3
$6.07M Buy
138,735
+18,256
+15% +$887K 1.01% 27
2022
Q2
$6.32M Buy
120,479
+3,098
+3% +$158K 0.96% 27
2022
Q1
$6.08M Buy
117,381
+18,379
+19% +$954K 0.75% 40
2021
Q4
$5.85M Buy
99,002
+14,314
+17% +$709K 0.73% 38
2021
Q3
$3.64M Sell
84,688
-249
-0.3% -$11K 0.5% 56
2021
Q2
$3.33M Buy
84,937
+14,817
+21% +$576K 0.45% 64
2021
Q1
$2.54M Sell
70,120
-3,826
-5% -$136K 0.36% 76
2020
Q4
$2.72M Sell
73,946
-1,738
-2% -$63.8K 0.41% 64
2020
Q3
$2.64M Sell
75,684
-8,206
-10% -$288K 0.44% 62
2020
Q2
$2.6M Buy
83,890
+18,491
+28% +$628K 0.48% 62
2020
Q1
$2.02M Sell
65,399
-15,187
-19% -$517K 0.47% 63
2019
Q4
$3M Sell
80,586
-7,990
-9% -$285K 0.53% 58
2019
Q3
$3.02M Sell
88,576
-8,340
-9% -$303K 0.58% 56
2019
Q2
$3.98M Sell
96,916
-457
-0.5% -$18.1K 0.79% 41
2019
Q1
$3.92M Sell
97,373
-1,699
-2% -$68K 0.8% 41
2018
Q4
$4.1M Sell
99,072
-687
-0.7% -$28.5K 0.94% 33
2018
Q3
$4.17M Sell
99,759
-441
-0.4% -$17K 0.79% 38
2018
Q2
$3.45M Sell
100,200
-9,808
-9% -$335K 0.71% 46
2018
Q1
$3.7M Buy
110,008
+3,088
+3% +$106K 0.78% 39
2017
Q4
$3.67M Buy
106,920
+2,807
+3% +$95.7K 0.76% 44
2017
Q3
$3.53M Sell
104,113
-16,384
-14% -$527K 0.75% 45
2017
Q2
$3.84M Sell
120,497
-61,950
-34% -$1.95M 0.85% 39
2017
Q1
$5.92M Sell
182,447
-15,072
-8% -$475K 1.38% 21
2016
Q4
$6.09M Sell
197,519
-18,288
-8% -$558K 1.45% 22
2016
Q3
$6.93M Buy
215,807
+2,208
+1% +$73.8K 1.65% 18
2016
Q2
$7.14M Buy
213,599
+8,711
+4% +$278K 1.67% 17
2016
Q1
$5.76M Sell
204,888
-1,318
-0.6% -$37.6K 1.41% 27
2015
Q4
$6.32M Buy
206,206
+9,223
+5% +$290K 1.52% 21
2015
Q3
$5.87M Buy
196,983
+3,734
+2% +$120K 1.45% 22
2015
Q2
$6.15M Buy
193,249
+13,756
+8% +$448K 1.42% 24
2015
Q1
$5.92M Buy
179,493
+116,377
+184% +$3.7M 1.35% 26
2014
Q4
$1.86M Buy
63,116
+2,115
+3% +$60.6K 0.43% 68
2014
Q3
$1.71M Sell
61,001
-235
-0.4% -$6.59K 0.41% 73
2014
Q2
$1.72M Buy
61,236
+2,452
+4% +$69.9K 0.4% 75
2014
Q1
$1.79M Buy
58,784
+8,947
+18% +$267K 0.44% 73
2013
Q4
$1.45M Sell
49,837
-1,599
-3% -$46.5K 0.36% 75
2013
Q3
$1.4M Sell
51,436
-5,726
-10% -$156K 0.35% 75
2013
Q2
$1.52M Buy
+57,162
New +$1.58M 0.32% 81

Other funds holding PFE

Cypress Capital Group's PFE Position: Q2 2026 in Review

Cypress Capital Group increased its Pfizer (PFE) stake by 6.3% in Q2 2026, buying an estimated $215K and bringing the position to 138,473 shares worth $3.33M. The position accounts for 0.31% of the portfolio, ranked #76.

Cypress Capital Group first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.37M in Q4 2022. 2,169 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Cypress Capital Group held 138,473 shares of Pfizer worth $3.33M as of Q2 2026.
  • Cypress Capital Group bought 8,227 Pfizer shares in Q2 2026, an estimated $215K.
  • Pfizer made up 0.31% of Cypress Capital Group's portfolio in Q2 2026, its #76 holding.
  • Cypress Capital Group first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Cypress Capital Group's Pfizer position peaked at $7.37M in Q4 2022.
  • 2,169 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Cypress Capital Group's 13F filing for Q2 2026, filed 5 Aug 2026.